STVN

+ Watchlist + Portfolio

Stevanato Group S.p.A.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $21.71
52-Week Range: $12.89 – $28.00
Market Cap: $6.10B
P/E (TTM): 38.53
EPS (TTM): 0.58
Dividend Yield: 0.28%

Advanced Metrics

Price/Book: 3.40
PEG Ratio: 0.37
Return on Equity: 9.13%
Return on Assets: 5.45%
Gross Margin: 29.40%
Operating Margin: 17.22%
Profit Margin: 10.99%
Current Ratio: 1.61
Debt/Equity: 0.29
Total Debt: $445.30M
Free Cash Flow: $-104.70M
Revenue Growth: 7.80%
Earnings Growth: -26.50%
Enterprise Value: $6.47B

STVN Income statement, annual periods, in EUR
EUR	FY2022	FY2023	FY2024	FY2025
Revenue	$983.68M	$1.09B	$1.10B	$1.19B
Cost of Revenue	$663.88M	$745.46M	$801.72M	$842.41M
Gross Profit	$319.80M	$339.89M	$302.32M	$343.88M
Research & Development	$34.39M	$35.67M	$31.67M	$25.44M
Selling, General & Admin	$111.83M	$104.90M	$109.13M	$119.06M
Operating Expenses	$127.37M	$139.17M	$141.18M	$145.07M
Operating Income	$192.43M	$200.72M	$161.14M	$198.80M
EBITDA	$256.40M	$272.35M	$247.80M	$284.15M
Pretax Income	$187.64M	$189.55M	$160.29M	$189.11M
Income Tax	$44.63M	$43.86M	$42.52M	$49.27M
Net Income	$142.85M	$145.63M	$117.78M	$139.84M
Diluted EPS	0.54	0.55	0.43	0.51
Diluted Shares	264.70M	264.98M	271.20M	273.00M

STVN Balance Sheet statement, annual periods, in EUR
EUR	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$228.74M	$69.60M	$98.27M	$130.60M
Receivables	$369.48M	$522.48M	$529.87M	$539.47M
Inventory	$213.25M	$255.32M	$245.22M	$268.25M
Current Assets	$845.77M	$861.89M	$880.12M	$943.35M
Total Assets	$1.66B	$2.07B	$2.33B	$2.54B
Current Liabilities	$462.50M	$574.39M	$477.47M	$535.88M
Long-Term Debt	$133.75M	$242.05M	$305.23M	$337.78M
Total Debt	$218.37M	$396.59M	$428.97M	$468.90M
Total Liabilities	$663.79M	$938.93M	$924.43M	$1.06B
Retained Earnings	$623.35M	$757.86M	$863.44M	$990.43M
Shareholders' Equity	$996.13M	$1.13B	$1.40B	$1.49B
Working Capital	$383.27M	$287.50M	$402.65M	$407.47M
Net Debt	—	$308.04M	$313.80M	$324.54M

STVN Cash Flow statement, annual periods, in EUR
EUR	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$103.31M	$105.21M	$155.78M	$286.08M
Capital Expenditure	-$243.13M	-$441.93M	-$313.57M	-$275.03M
Free Cash Flow	-$139.81M	-$336.72M	-$157.79M	$11.04M
Depreciation & Amortisation	$64.82M	$78.48M	$80.65M	$88.57M
Investing Cash Flow	-$242.95M	-$421.22M	-$310.21M	-$272.92M
Financing Cash Flow	-$44.54M	$158.03M	$183.22M	$22.06M
Dividends Paid	-$13.50M	-$14.29M	-$14.46M	-$14.74M
Net Change in Cash	-$184.17M	-$157.98M	$28.78M	$35.22M

STVN Income statement, quarterly periods, in EUR
EUR	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$256.60M	$280.00M	$303.17M	$346.48M	$273.57M
Cost of Revenue	$186.71M	$201.40M	$214.67M	$239.58M	$198.40M
Gross Profit	$69.89M	$78.60M	$88.50M	$106.90M	$75.18M
Research & Development	$5.93M	$6.00M	$7.65M	$5.81M	$5.84M
Selling, General & Admin	$27.81M	$32.10M	$30.85M	$25.66M	$29.96M
Operating Expenses	$35.26M	$37.20M	$35.78M	$36.81M	$36.44M
Operating Income	$34.63M	$41.40M	$52.72M	$70.08M	$38.74M
EBITDA	$57.16M	$50.60M	$50.90M	$91.95M	$65.06M
Pretax Income	$35.11M	$39.10M	$49.13M	$65.76M	$39.24M
Income Tax	$8.60M	$9.40M	$13.06M	$18.21M	$11.21M
Net Income	$26.52M	$29.70M	$36.06M	$47.55M	$28.03M
Diluted EPS	0.10	0.11	0.13	0.17	0.10
Diluted Shares	272.91M	272.90M	273.00M	273.00M	273.02M

STVN Balance Sheet statement, quarterly periods, in EUR
EUR	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$90.70M	$94.20M	$113.33M	$130.60M	$111.67M
Receivables	$487.62M	$480.70M	$489.92M	$539.47M	$506.66M
Inventory	$261.70M	$274.10M	$274.69M	$268.25M	$294.36M
Current Assets	$845.47M	$860.60M	$884.47M	$943.35M	$914.36M
Total Assets	$2.32B	$2.35B	$2.41B	$2.54B	$2.58B
Current Liabilities	$463.26M	$481.50M	$467.42M	$535.88M	$560.27M
Long-Term Debt	$302.02M	$331.60M	$358.04M	$337.78M	$312.57M
Total Debt	$396.30M	$418.20M	$450.33M	$468.90M	$448.52M
Total Liabilities	$908.28M	$953.20M	$976.72M	$1.06B	$1.05B
Retained Earnings	$890.85M	—	—	$990.43M	$1.02B
Shareholders' Equity	$1.42B	$1.40B	$1.44B	$1.49B	$1.53B
Working Capital	$382.21M	$379.10M	$417.05M	$407.47M	$354.09M
Net Debt	$287.15M	$306.14M	$322.89M	$324.54M	$320.22M

STVN Cash Flow statement, quarterly periods, in EUR
EUR	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$99.84M	$44.90M	$47.23M	$94.11M	$75.49M
Capital Expenditure	-$71.79M	-$60.27M	-$48.39M	-$94.59M	-$70.72M
Free Cash Flow	$28.05M	$44.90M	-$61.42M	-$485.00K	$4.77M
Depreciation & Amortisation	$20.62M	$21.57M	$21.78M	$24.59M	$24.65M
Investing Cash Flow	-$70.71M	-$59.70M	-$48.15M	-$94.36M	-$70.40M
Financing Cash Flow	-$35.75M	$21.20M	$19.43M	$17.19M	-$24.93M
Dividends Paid	—	—	—	$0.00	—
Net Change in Cash	-$6.63M	$6.46M	$18.45M	$16.94M	-$19.84M

Market Snapshot

About

Stevanato Group is a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. The company manufactures glass vials, syringes, cartridges, and other critical components for injectable drugs and vaccines. Stevanato also provides engineering and assembly services for medical devices and diagnostic applications.